Your Trusted Brand for Over 35 Years

Congestive Heart Failure References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. American Heart Association. Heart Disease and Stroke Statistics—2004 Update . Dallas , Tex : American Heart Association; 2004.
  2. McCullough PA, Philbin EF, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study . J Am Coll Cardiol. 2002;39:60-69 .
  3. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
  4. Braunwald E. Heart failure. In: Braunwald E, Fauci AS, et al, eds. Harrison's Principles of Internal Medicine. 15th ed. New York , NY : McGraw Hill Professional Publishing; 2001:1318-1328.
  5. Kostis JB, Shelton BJ, et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. Am Heart J. 1994;128:358-364.
  6. Hunt SA, Baker DW, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant. 2002;21:189-203.
  7. Witte KK , Nikitin NP , et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J. 2005
  8. Fugh-Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. Prev Cardiol. 2000;3:24-32.
  9. Schaffer SW, Lombardini JB, et al. Interaction between the actions of taurine and angiotensin II. Amino Acids. 2000;18:305-318.
  10. Dzau VJ, Colucci WS, et al. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981;63:645-651.
  11. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int. 1987;31:1402-1415.
  12. Ahmed A. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice. J Am Geriatr Soc. 2003;51:123-126.
  13. Adlam D , Silcocks P , et al. Using BNP to develop a risk score for heart failure in primary care. Eur Heart J . 2005;26:1086-1093.
  14. Steg PG , Joubin L , et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest. 2005;128:21-29.
  15. Zile MR , Brutsaert DL . New concepts in diastolic dysfunction and diastolic heart failure, part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387-1393.
  16. Benedict CR, Johnstone DE , et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol. 1994;23:1410-1420.
  17. Moriyama Y, Yasue H, et al. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab. 2000;85:1834-1840.
  18. Kontoleon PE, Anastasiou-Nana MI, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol. 2003;87:179-183.
  19. Anker SD , Chua TP , et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526-534.
  20. Jankowska EA, Rozentryt P, Ponikowska B. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009 May 13;301(18):1892-901.
  21. Pugh PJ, Jones RD , et al. Testosterone treatment for men with chronic heart failure. Heart. 2004;90:446-447.
  22. Dzugan SA, Arnold Smith R. Hypercholesterolemia treatment: a new hypothesis or just an accident? Med Hypotheses. 2002;59:751-756.
  23. Fedak PW, Verma S, et al. Cardiac remodeling and failure: from molecules to man (part I). Cardiovasc Pathol. 2005;14:1-11.
  24. Weisberg AD, Albornoz F, et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotension II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol. 2005;25:365-371.
  25. Awata N, et al. The effects of coenzyme Q10 on ischemic heart disease evaluated by dynamic exercise test. In: Yamamura Y, Folkers K, et al, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 2. Amsterdam , Netherlands : Elsevier-North Holland Biomedical; 1980:247-254.
  26. Crane FL , Navas P. The diversity of coenzyme Q function. Mol Aspects Med. 1997;18(suppl):S1-S6.
  27. Nakamura Y, Takahashi M, et al. Protection of ischaemic myocardium with coenzyme Q10. Cardiovasc Res. 1982;16:132-137.
  28. Nayler WG. The use of coenzyme Q10 to protect ischaemic heart muscle. In: Yamamura Y, Folkers K, et al, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 2. Amsterdam , Netherlands : Elsevier-North Holland Biomedical; 1980:409-425.
  29. Frei B, Kim MC, et al. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci USA . 1990;87:4879-4883.
  30. Ondarroa M, Quinn PJ. Proton magnetic resonance spectroscopic studies of the interaction of ubiquinone-10 with phospholipid model membranes. Eur J Biochem. 1986;155:353-361.
  31. Weant KA , Smith KM . The role of coenzyme Q10 in heart failure. Ann Pharmacother. 2005;39:1522-1526.
  32. Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure; rationale, design and end-points of “Q-symbio”—a multinational trial. Biofactors. 2003;18:79-89.
  33. Berman M, Erman A, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol. 2004;27:295-299.
  34. Jeejeebhoy F, Keith M, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J. 2002;143:1092-1100.
  35. Taggart DP, Jenkins M, et al. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. Ann Thorac Surg. 1996;61:829-833.
  36. Judy WV, Folkers K, et al. Improved long-term survival in coenzyme Q10 treated chronic heart failure patients compared to conventionally treated patients. In: Folkers K, Littarru GP, et al, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 4. Amsterdam , Netherlands : Elsevier Science;1991:291-298.
  37. Hosoe K, Kitano M, Kishida H, et al. Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers. Regul Toxicol Pharmacol. 2007 Feb;47(1):19-28.
  38. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50.
  39. Shults CW, Flint BM, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s disease. Exp Neurol. 2004 Aug;188(2):491-4.
  40. Langsjoen P. 5th Annual International CoQ10 Symposium. Kobe, Japan: November 9-12, 2007.
  41. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9(2-4):273-84.
  42. Langsjoen PH, Littarru GP, Silver MA. Role of concomitant coenzyme Q10 with statins for patients with hyperlipidemia. Curr Topics Nutr Res.2005;3(3):149–58.
  43. Langsjoen PH, Langsjoen AM. Coenzyme Q10 in cardiovascular disease with emphasis on heart failure and myocardial ischaemia. Asia Pacific Heart J. 1998;7(3):160-8.
  44. Goa KL, Brogden RN. L-carnitine: a preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs. 1987;34:1-24.
  45. Mancini M, Rengo F, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. A rzneimittelforschung. 1992;42:1101-1104.
  46. Pucciarelli G, Mastursi M, et al. The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure . Clin Ter. 1992;141:379-384.
  47. Colonna P, Iliceto S. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. Am Heart J. 2000;139(pt 3):S124-S130.
  48. Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J. 2002;143:910-915.
  49. Schwinger RH, Pietsch M, et al. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol. 2000;35:700-707.
  50. Tauchert M, Gildor A, et al. High-dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure . Herz. 1999;24:465-474.
  51. Leuchtgens H. Crataegus Special Extract WS 1442 in NYHA II heart failure: a placebo controlled randomized double-blind study. Fortschr Med. 1993;111:352-354.
  52. Schmidt U, et al. Efficacy of the hawthorn (Crataegus) preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. Phytomedicine. 1994;1:17-24.
  53. Weikl A, Assmus KD, et al. Crataegus Special Extract WS 1442: assessment of objective effectiveness in patients with heart failure (NYHA II). Fortschr Med. 1996;114:291-296.
  54. Cohen N, Alon I, et al. Metabolic and clinical effects of oral magnesium supplementation in furosemide-treated patients with severe congestive heart failure. Clin Cardiol. 2000;23:433-436.
  55. Maxwell SR. Can anti-oxidants prevent ischaemic heart disease? J Clin Pharm Ther. 1993;18:85-95.
  56. Eichholzer M, Stahelin HB, et al. Inverse correlation between essential antioxidants in plasma and subsequent risk to develop cancer, ischemic heart disease and stroke respectively: 12-year follow-up of the Prospective Basel Study. EXS. 1992;62:398-410.
  57. Patrick L. Mercury toxicity and antioxidants, part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. Alter Med Rev. 2002;7:456-471.
  58. Carlson DA, et al. The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects. Altern Med Rev. 2007 Dec;12(4):343-51.
  59. Berger MM , Mustafa I . Metabolic and nutritional support in acute cardiac failure. Curr Opin Clin Nutr Metab Care. 2003;6:195-201.
  60. Witte KK , Clark AL . Fish oils—adjuvant therapy in chronic heart failure? Eur J Cardiovasc Prev Rehabil. 2004;11:267-274.
  61. Omran H, Illien S, MacCarter D, St CJ, Luderitz B. D-Ribose improves diastolic function and quality of life in congestive heart failure patients: a prospective feasibility study. Eur J Heart Fail. 2003 Oct;5(5):615-9.
  62. Achinger SG, Ayus JC. The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int Suppl. 2005 Jun;(95):S37-S42.
  63. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007 Feb;18(2):613-20.
  64. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003 Jan 1;41(1):105–12.
  65. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006 Apr;83(4):754-9.
  66. Chowanadisai W, Bauerly KA, Tchaparian E, Wong A, Cortopassi GA, Rucker RB. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. J Biol Chem. 2010 Jan 1;285(1):142-52.
  67. Karamanlidis G, Nascimben L, Couper GS, Shekar PS, del Monte F, Tian R. Defective DNA replication impairs mitochondrial biogenesis in human failing hearts. Circ Res. 2010 May 14;106(9):1541-8.
  68. Andrews R, et al. The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J 1998 Apr; 19(4): 617-22.
  69. Bemben MG, Lamont HS. Creatine supplementation and exercise performance: recent findings. Sports Med. 2005;35(2):107-25.